Isofol Medical AB(DE:5IU)
€0.12+-0.01 (+12.38%)
DE:5IU
Isofol Medical AB financials statements
€0.12
At close:+-0.01 (+12.38%)
Isofol Medical AB (5IU) Ratios
1 Followers
Isofol Medical AB Ratios
DE:5IU's free cash flow for Q2 2026 was kr-14.06M. For the 2026 fiscal year, DE:5IU's free cash flow was increased by kr0.00 and operating cash flow was kr-14.06M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.19 | 4.96 | 7.70 | 4.14 | 4.75 |
| Quick Ratio | 6.19 | 4.96 | 7.70 | 4.14 | 4.75 |
| Cash Ratio | 2.01 | 4.85 | 7.57 | 3.77 | 4.57 |
| Solvency Ratio | -2.52 | -2.12 | -1.93 | -2.90 | -2.39 |
| Operating Cash Flow Ratio | -2.48 | -2.12 | -2.88 | -3.78 | -2.27 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -122.20 |
| Net Current Asset Value | kr 107.87M | kr 77.94M | kr 121.43M | kr 154.47M | kr 311.48M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.20 | 1.26 | 1.16 | 1.35 | 1.26 |
| Debt Service Coverage Ratio | -54761.00 | 0.00 | 0.00 | 0.00 | -114.11 |
| Interest Coverage Ratio | -54761.00 | 0.00 | 0.00 | 0.00 | -1217.05 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 |
| Net Debt to EBITDA | 0.77 | 2.04 | 3.73 | 1.17 | 1.90 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | -4773.23% | -1294.89% | -777.90% |
| EBIT Margin | 0.00% | 0.00% | -5140.22% | -1248.68% | -892.95% |
| EBITDA Margin | 0.00% | 0.00% | -5135.09% | -1248.15% | -885.83% |
| Operating Profit Margin | 0.00% | 0.00% | -5781.28% | -1308.59% | -912.51% |
| Pretax Profit Margin | 0.00% | 0.00% | -5141.61% | -1248.38% | -893.70% |
| Net Profit Margin | 0.00% | 0.00% | -5141.61% | -1248.68% | -893.70% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -5141.61% | -1248.68% | -893.70% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.02% | 100.00% |
| EBT Per EBIT | 98.92% | 92.12% | 88.94% | 95.40% | 97.94% |
| Return on Assets (ROA) | -41.86% | -44.19% | -26.37% | -74.86% | -49.89% |
| Return on Equity (ROE) | -50.22% | -55.79% | -30.53% | -100.83% | -62.93% |
| Return on Capital Employed (ROCE) | -50.48% | -60.07% | -34.07% | -102.78% | -64.23% |
| Return on Invested Capital (ROIC) | -50.48% | -60.07% | -34.07% | -99.39% | -62.54% |
| Return on Tangible Assets | -41.86% | -44.19% | -26.37% | -74.86% | -49.89% |
| Earnings Yield | -34.29% | -12.16% | -31.51% | -133.69% | -17.25% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.34 | 22.89 | 13.74 |
| Payables Turnover | 0.00 | 19.10 | 17.67 | 22.68 | 12.74 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 240.33 | 3.19 | 12.83 |
| Asset Turnover | 0.00 | 0.00 | 0.01 | 0.06 | 0.06 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.01 | 0.05 | 0.12 |
| Cash Conversion Cycle | 0.00 | -19.11 | 1065.24 | -0.15 | -2.07 |
| Days of Sales Outstanding | 0.00 | 0.00 | 1085.89 | 15.94 | 26.57 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 19.11 | 20.65 | 16.09 | 28.64 |
| Operating Cycle | 0.00 | 0.00 | 1085.89 | 15.94 | 26.57 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.24 | -0.26 | -0.33 | -1.18 | -1.50 |
| Free Cash Flow Per Share | -0.24 | -0.26 | -0.33 | -1.18 | -1.50 |
| Dividend Paid and CapEx Coverage Ratio | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | -48.37 | -114.06 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -72.87 | -14.92 | -8.41 |
| Free Cash Flow Yield | -32.88% | -11.74% | -44.65% | -159.78% | -16.23% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.92 | -8.22 | -3.17 | -0.75 | -5.80 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 163.19 | 9.34 | 51.81 |
| Price-to-Book (P/B) Ratio | 1.46 | 4.59 | 0.97 | 0.75 | 3.65 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.04 | -8.52 | -2.24 | -0.63 | -6.16 |
| Price-to-Operating Cash Flow Ratio | -3.04 | -8.52 | -2.24 | -0.63 | -6.16 |
| Price-to-Earnings Growth (PEG) Ratio | 0.39 | -0.47 | 0.04 | 0.02 | 0.17 |
| Enterprise Value Multiple | -2.12 | -5.54 | 0.55 | 0.42 | -3.95 |
| Enterprise Value | 115.96M | 261.41M | -20.49M | -67.11M | 783.17M |
| EV to EBITDA | -2.12 | -5.54 | 0.55 | 0.42 | -3.95 |
| EV to Sales | 0.00 | 0.00 | -28.42 | -5.24 | 34.95 |
| EV to Free Cash Flow | -2.23 | -6.23 | 0.39 | 0.35 | -4.16 |
| EV to Operating Cash Flow | -2.23 | -6.23 | 0.39 | 0.35 | -4.16 |
| Tangible Book Value Per Share | 0.50 | 0.48 | 0.75 | 0.98 | 2.53 |
| Shareholders’ Equity Per Share | 0.50 | 0.48 | 0.75 | 0.98 | 2.53 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.08 | 0.18 |
| Net Income Per Share | -0.25 | -0.27 | -0.23 | -0.99 | -1.59 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.99 | 0.92 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 8.78 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.96 | 0.97 | 1.42 | 1.20 | 0.94 |
Currency in SEK
